Microbot Medical Inc stock (US5950101098): Liberty launch drives first-quarter revenue and raises investor attention

Microbot Medical Inc has reported its first meaningful first-quarter revenue, supported by the initial launch phase of its Liberty endovascular robotic system, while the Nasdaq-listed stock remains volatile and closely watched by short sellers.

Microbot Medical Inc has moved into a new phase of its development by reporting first-quarter revenue linked to the initial launch of its Liberty endovascular robotic system, according to a shareholder and analyst call transcript published on May 14, 2026, by MarketScreener based on company communications (MarketScreener as of 05/14/2026). At the same time, the Nasdaq-listed stock continues to trade with high volatility and a notable short interest level, with 12.04% of the public float sold short as of April 30, 2026, according to MarketBeat data (MarketBeat as of 05/01/2026).

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Microbot Medical Inc
• Sector/industry: Medical devices, robotic-assisted endovascular procedures
• Headquarters/country: Hingham, Massachusetts, United States
• Core markets: United States and other developed healthcare markets
• Key revenue drivers: Liberty endovascular robotic system and related consumables
• Home exchange/listing venue: Nasdaq Capital Market (ticker: MBOT)
• Trading currency: US dollar (USD)

Microbot Medical Inc: core business model

Microbot Medical Inc is a development-stage medical device company focused on robotic-assisted interventions in the vascular system. Its core objective is to improve the precision and safety of minimally invasive procedures using proprietary micro-robotic technologies and a remotely operated platform. The company targets hospitals and interventional centers that treat complex cardiovascular and neurovascular conditions, which require high accuracy and controlled catheter navigation.

The Liberty endovascular robotic system is Microbot Medical’s flagship technology and sits at the heart of its business strategy. Liberty is designed as a single-use, disposable robotic platform that can be operated remotely, aiming to reduce radiation exposure for physicians, standardize procedures and potentially shorten learning curves for complex interventions. The model is oriented around selling robotic disposables and compatible accessories, in addition to future service and software elements once installations expand.

Microbot Medical remains pre-profit and still heavily dependent on external funding while it scales up its commercialization activities. The company has recorded a net loss of about 13.14 million USD over the last four reported quarters and a trailing earnings per share of -0.26 USD, according to MarketBeat’s earnings overview updated in 2026 (MarketBeat as of 05/01/2026). This underlines how much of the current business model is still centered on research, clinical validation and early-stage commercialization rather than established recurring profit streams.

From a strategic perspective, Microbot Medical seeks to position Liberty as a differentiated solution within the broader interventional robotics market. Management emphasizes the single-use nature of the platform and the potential to integrate with existing imaging suites rather than requiring a large fixed robotic installation. This approach is intended to lower barriers for adoption by hospitals that may not have the capital budget or space for traditional floor-mounted robotic systems, particularly in community settings or smaller centers that still perform advanced endovascular procedures.

Main revenue and product drivers for Microbot Medical Inc

The company’s main future revenue driver is expected to be the Liberty endovascular robotic system, together with disposable components that are used for each procedure. During the shareholder and analyst call referenced in mid-May 2026, Microbot Medical indicated that its reported first-quarter revenue was supported by initial Liberty-related activities, marking a step beyond the purely pre-commercial phase (MarketScreener as of 05/14/2026). Although the revenue level was still modest, the disclosure signals that the Liberty platform is beginning to translate into actual sales.

Clinical and regulatory milestones are another key driver of Microbot Medical’s long-term revenue potential. The company’s ability to broaden the list of procedures, indications and geographies where Liberty can be used will help determine the addressable market size. Typically, robotic systems in cardiology, peripheral vascular and neurovascular interventions must meet strict safety and efficacy requirements, and Microbot Medical’s path through US and international regulatory pathways is closely watched by investors who follow medtech and small-cap life sciences names.

Beyond initial installations, the economic model for Liberty is likely to rely heavily on recurring revenue from disposables. Hospitals that adopt the system would need a new sterile disposable unit for each procedure, which creates a high-margin, repeat business stream if utilization is solid. Service contracts, training fees and possible software updates may add to that recurring revenue base once the commercial footprint expands. For now, however, Microbot Medical’s reported figures show that the company is still in an early launch phase, with accumulated losses and negative earnings per share reflecting the ongoing investment cycle.

The company’s earnings history underscores this ramp-up phase. Over the last four quarters, Microbot Medical generated a combined net income of approximately -13.14 million USD and an EPS of -0.26 USD, according to MarketBeat’s trailing data (MarketBeat as of 05/01/2026). In its most recently reported quarter, the company posted a loss per share of about -0.05 USD, which came in better than an analyst consensus estimate of around -0.08 USD per share for that period, highlighting how cost control and operating discipline can still positively surprise the market even in a pre-revenue-heavy phase.

Forward-looking expectations also reflect the continuing investment period. MarketBeat shows that consensus estimates currently anticipate a full-year loss of roughly -0.34 USD per share over the coming year, suggesting that profitability remains a medium-term goal rather than an immediate outcome (MarketBeat as of 05/01/2026). For investors, this dynamic places the focus on execution milestones, commercialization traction and capital structure management instead of near-term earnings metrics.

Conclusion

Microbot Medical Inc has taken a visible step forward by reporting first-quarter revenue tied to the initial launch of its Liberty endovascular robotic system, while still operating in a loss-making, investment-intensive phase. Trailing figures show a net loss of about 13.14 million USD and negative earnings per share, and consensus expectations continue to point to a full-year loss as commercialization efforts ramp up. For US-focused investors watching innovative medtech names on Nasdaq, Liberty’s clinical adoption, regulatory progress and the company’s ability to convert early interest into recurring disposable revenue will likely remain decisive factors, alongside careful monitoring of short interest and capital needs.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.